Loading organizations...

§ Private Profile · Berlin, Berlin, Germany
Synthetic biology company developing sustainable biomaterials and advanced proteins for consumer products, focused on vegan collagen.
Based in Berlin, Germany, Cambrium is a biotechnology company that utilizes synthetic biology, machine learning, and artificial intelligence to develop sustainable biomaterials and high-performance proteins for consumer products. The organization primarily focuses on creating specialty chemicals and bio-based ingredients for the cosmetics, personal care, textiles, and nutraceutical sectors, highlighted by its flagship product, NovaColl, a vegan, skin-identical collagen. Following the commercial launch of its initial skincare applications in early 2023, the enterprise projected its engineered materials would reach approximately 50,000 end users by the close of that year. To support its ongoing research and commercialization efforts, the firm has secured $13.53 million in total funding across pre-seed and seed rounds from institutional investors including Essential Capital, Valor Equity Partners, and Merantix. Cambrium was officially established in 2020 by co-founders Mitchell Duffy and Charlie Cotton.
Cambrium has raised $8.5M across 1 funding round.
Cambrium has raised $8.5M in total across 1 funding round.
Cambrium has raised $8.5M across 1 funding round. Most recently, it raised $8.5M Seed in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 31, 2023 | $8.5M Seed | RON Zori | HOF Capital, SNR, Valor Equity Partners | Announced |
Cambrium has raised $8.5M in total across 1 funding round.
Cambrium's investors include Ron Zori, HOF Capital, SNR, Valor Equity Partners.